Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Viewpoint

YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer

Alexander Hergovich

Author Affiliations

UCL Cancer Institute, University College London, WC1E 6BT, London, UK

Breast Cancer Research 2012, 14:326  doi:10.1186/bcr3349

Published: 5 December 2012

Abstract

The proto-oncogenes YAP and TAZ have previously gained much attention as downstream effectors of Hippo tumour suppressor signalling. While the regulation of YAP/TAZ by MST/LATS kinases is reasonably well understood, the nature of factors functioning upstream of MST/LATS is yet to be elucidated in detail. A recent paper by Ma and co-workers defines a novel role for leukemia inhibitory factor receptor (LIFR) signalling upstream of the Hippo-YAP pathway in breast cancer metastasis. Moreover, a whole genome in vivo RNA interference screen by Lippmann and colleagues identified LIFR as a breast tumour suppressor. Here, we discuss the implications of these studies for breast cancer research and treatment.